Filing Details

Accession Number:
0000899243-21-042794
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-03 18:00:17
Reporting Period:
2021-11-01
Accepted Time:
2021-11-03 18:00:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596946 Quotient Ltd QTNT In Vitro & In Vivo Diagnostic Substances (2835) 264719797
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1605065 Brian Mcdonough 28 Esplanade
St Helier Y9 JE2 3QA
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-11-01 1,236 $0.00 61,870 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 53,040 Indirect By the McDonough-McGuire Joint Revocable Trust
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Ordinary Shares Ordinary Shares Option (Right to buy) $8.00 2024-04-29 10,000 10,000 Direct
Ordinary Shares Options to purchase ordinary shares $0.00 2014-11-14 2022-08-30 40,029 40,029 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $9.95 2024-10-31 5,025 5,025 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $11.62 2025-10-31 4,303 4,303 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $5.73 2026-10-31 8,726 8,726 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $5.21 2027-10-31 9,597 9,597 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $6.41 2028-10-31 6,240 6,240 Direct
Ordinary Shares Ordinary Shares Option (Right to buy) $7.78 2029-10-31 8,158 8,158 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $4.55 2030-10-31 13,611 13,611 Direct
Ordinary Shares Restricted Stock Units $0.00 27,668 27,668 Direct
Ordinary Shares Ordinary Share Option (Right to Buy) $2.53 2031-10-31 24,040 24,040 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-04-29 10,000 10,000 Direct
2022-08-30 40,029 40,029 Direct
2024-10-31 5,025 5,025 Direct
2025-10-31 4,303 4,303 Direct
2026-10-31 8,726 8,726 Direct
2027-10-31 9,597 9,597 Direct
2028-10-31 6,240 6,240 Direct
2029-10-31 8,158 8,158 Direct
2030-10-31 13,611 13,611 Direct
27,668 27,668 Direct
2031-10-31 24,040 24,040 Direct
Footnotes
  1. All 10,000 options have vested and remain exercisable.
  2. The exercise price will be paid in pounds sterling, at GBP 0.91 per share.
  3. All 5,025 options have vested and remain exercisable.
  4. All 4,303 options have vested and remain exercisable.
  5. All 8,726 options have vested and remain exercisable.
  6. Restricted Stock Units convert into ordinary shares on a one-for-one basis.
  7. All 9,597 options have vested and remain exercisable.
  8. All 6,240 options have vested and remain exercisable.
  9. The Reporting Person and his spouse are Co-Trustees of their successors in trust, of the McDonough-McGuire Joint Revocable Trust, dated May 14, 2013. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these ordinary shares in this report shall not be deemed an admission of beneficial ownership of all of the reported ordinary shares for purposes of Section 16 or for any other purpose.
  10. 2,719 options vested on October 31, 2021 and remain exercisable, and the remaining 2,720 options will vest on October 31, 2022.
  11. All 13,611 options have vested and remain exercisable.
  12. On October 31, 2021, the Reporting Person was granted 27,668 restricted stock units, vesting in four equal installments on January 31, 2022, April 30, 2022, July 31, 2022 and October 31, 2022.
  13. The options vest and become exercisable on October 31, 2022.
  14. The sale reported on this Form 4 is a sale to cover taxes arising from the vesting and settlement of RSU awards. This sale is mandated by the Reporting Person's election to fund such taxes by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer.